How are pharma deal valuations typically calculated?

Pharma assets are valued using risk-adjusted NPV models that discount projected cash flows by probability of technical success (PTS) at each development stage. A Phase 3 oncology asset with 60% PTS and $3B peak sales might be valued at $8-12B depending on patent runway, competitive landscape, and therapeutic differentiation.